Retrospective Data Analysis in Crohn's Disease
- Conditions
- Crohn's Disease
- Registration Number
- NCT01363427
- Lead Sponsor
- Ferring Pharmaceuticals
- Brief Summary
The purpose of this study is to identify prognostic parameters about efficacy of Mesalazine in recently diagnosed patients with Morbus Crohn by retrospective data collection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 161
- therapeutic need according to SPC
- written informed consent
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to Mesalazine: measured by time to step up therapy 12 to 48 months
- Secondary Outcome Measures
Name Time Method Identification and characterisation of the responding sub-population 12 to 48 months measured by: (a) Age at diagnosis, (b) Proportion of patients with minor endoscopic lesions, (c) Lack of severe mucosal lesions (Adapted Rutgeerts Score \< 2)
Trial Locations
- Locations (16)
Investigational Site, Ehrenfelsstraße 47
🇩🇪Berlin, Germany
Investigational Site, Am Tiefen Weg 2
🇩🇪Karlstadt, Germany
Investigational Site, Münchner Straße 64
🇩🇪Dachau, Germany
Investigational Site, Hohenfelder Straße 20
🇩🇪Koblenz, Germany
Investigational Site, Graseggerstraße 105
🇩🇪Köln, Germany
Investigational Site, Franz-Kail-Straße 2
🇩🇪Leverkusen, Germany
Investigational Site, Uferstraße 3
🇩🇪Minden, Germany
Investigational Site, Erdbeerfeld 8
🇩🇪Kiel-Altenholz, Germany
Investigational Site, Bahnhofplatz 2
🇩🇪Mainz, Germany
Investigational Site, Funkenburgstraße 19
🇩🇪Leipzig, Germany
Investigational Site, Karlsbader Straße 7
🇩🇪Dinkelsbühl, Germany
Investigational Site, Heiligengrabstraße 16
🇩🇪Hof, Germany
Investigational Site, Möllendorfstraße 111
🇩🇪Berlin, Germany
Investigational Site, Weiltinger Str. 11
🇩🇪Nürnberg, Germany
Investigational Site, Hammer Straße 95
🇩🇪Münster, Germany
Investigational Site, Marktplatz 23
🇩🇪Rottenburg, Germany